

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**(1) CHANGE OF NON-EXECUTIVE DIRECTOR; AND
(2) CHANGE IN COMPOSITION OF STRATEGY COMMITTEE**

CHANGE OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”) hereby announces that Dr. Yibing Wu (“**Dr. Wu**”) has tendered his resignation as a non-executive Director and a member of the strategy committee of the Board (the “**Strategy Committee**”), with effect from November 20, 2024 in order to devote more time to his other personal commitment.

Dr. Wu has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude to Dr. Wu for his valuable contribution to the Company during his tenure of service as a non-executive Director and a member of the Strategy Committee.

The Board is also pleased to announce that Ms. Jingwen Miao (“**Ms. Miao**”) has been appointed as a non-executive Director with effect from November 20, 2024.

The biographical details of Ms. Miao are as follows:

Ms. Jingwen Miao, aged 38, is currently a managing director at Temasek International Pte. Ltd., where she joined in October 2014, and is responsible for overseeing investment efforts in the life sciences sector in China. Ms. Miao began her career in 2008 with Morgan Stanley Investment Banking Division, focusing on providing financial advisory services to clients in the transportation and industrials sectors. In 2010, she entered the private equity industry and joined The Carlyle Group's Asia Buyout Fund focusing on investment in various sectors including healthcare, consumer, retails and industrials. Ms. Miao obtained a bachelor's degree in business administration from Fudan University in 2008.

Ms. Miao does not, at present, nor did she in the past three years, hold any directorship in any public companies the securities of which are listed in Hong Kong or overseas.

Ms. Miao has entered into a director's service agreement with the Company for a term of three years which is terminable by either party with three months' written notice, and she is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. Ms. Miao does not have any relationships with any Directors or senior management or substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Ms. Miao did not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Ms. Miao will not receive any director's fee for her term of appointment.

Save as disclosed above, there is no other information which is discloseable nor is/was Ms. Miao involved in any of the matters required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there are no other matters relating to Ms. Miao's appointment that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

CHANGE IN COMPOSITION OF STRATEGY COMMITTEE

The Board further announces that Ms. Miao has been appointed as a member of the Strategy Committee with effect from November 20, 2024.

The Board would like to extend its warmest welcome to Ms. Miao on her new appointment.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, November 20, 2024

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen as executive Director; Dr. Ge Li, Dr. Weichang Zhou, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*